Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dorzolamide Hydrochloride

FDA-approved product (solution/drops, ophthalmic), marketed as Dorzolamide Hydrochloride, Trusopt.

Registered studies
50+
Lab records
4
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Dorzolamide Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Glaucoma
  • Ocular hypertension
  • Open-angle glaucoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Carbonic anhydrase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis86.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 4 of 4 lab records
Open Dorzolamide Hydrochloride in ChEMBL Registered studies below
Show the 4 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dorzolamide Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparative Study of Dorzotimol Eye Drops, 20 mg/mL + 5 mg/mL Versus Cosopt® Eye Drops, 20 mg/mL + 5 mg/mL

    NCT05973318 · start 2017-04-10

    Registered record
    Registry ID
    NCT05973318
    Conditions
    Primary Open Angle Glaucoma of Both Eyes
    Interventions
    Dorzotimol eye drops, 20 mg/mL + 5 mg/mL; Cosopt eye drops, 20 mg/mL + 5 mg/mL
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-04-10
    Completion
    2018-09-17
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Open Angle Glaucoma of Both Eyes
    InterventionDorzotimol eye drops, 20 mg/mL + 5 mg/mL; Cosopt eye drops, 20 mg/mL + 5 mg/mL
    PhasePhase 3
    Registry statusCompleted

  • Comparative Study of Dorzol Eye Drops, 20 mg/ml Versus Trusopt® Eye Drops, 20 mg/ml

    NCT05973305 · start 2017-04-05

    Registered record
    Registry ID
    NCT05973305
    Conditions
    Primary Open Angle Glaucoma of Both Eyes
    Interventions
    Dorzol 20 mg/ml; Trusopt 20 mg/ml
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-04-05
    Completion
    2018-09-01
    Enrolment
    118

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Open Angle Glaucoma of Both Eyes
    InterventionDorzol 20 mg/ml; Trusopt 20 mg/ml
    PhasePhase 3
    Registry statusCompleted

  • Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)

    NCT03257813 · start 2016-04-01

    Registered record
    Registry ID
    NCT03257813
    Conditions
    Primary Open Angle Glaucoma; Ocular Hypertension
    Interventions
    PRO-122; Krytantek Ofteno®
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-04-01
    Completion
    2017-06-18
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Open Angle Glaucoma; Ocular Hypertension
    InterventionPRO-122; Krytantek Ofteno®
    PhasePhase 3
    Registry statusCompleted

  • Stop Retinal Ganglion Cell Dysfunction Study

    NCT02390284 · start 2015-09

    Registered record
    Registry ID
    NCT02390284
    Conditions
    Glaucoma
    Interventions
    Latanoprost; Bimatoprost; Travoprost; Timolol; Dorzolamide; Brinzolamide; Acetazolamide; Methazolamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-09
    Completion
    2024-10-04
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionLatanoprost; Bimatoprost; Travoprost; Timolol +4 more
    PhasePhase 3
    Registry statusTerminated

  • Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.

    NCT02571972 · start 2015-02-01

    Registered record
    Registry ID
    NCT02571972
    Conditions
    Wet Macular Degeneration; Age-related Macular Degeneration; Diabetic Macular Edema; Retinal Vein Occlusion
    Interventions
    Dorzolamide-timolol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-02-01
    Completion
    2015-12-20
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWet Macular Degeneration; Age-related Macular Degeneration; Diabetic Macular Edema; Retinal Vein Occlusion
    InterventionDorzolamide-timolol
    PhasePhase 2
    Registry statusCompleted

  • Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution

    NCT02325518 · start 2014-12

    Registered record
    Registry ID
    NCT02325518
    Conditions
    Open-Angle Glaucoma; Ocular Hypertension
    Interventions
    Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension; Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution; Subject's habitual PGA monotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-12
    Completion
    2015-12
    Enrolment
    218

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-Angle Glaucoma; Ocular Hypertension
    InterventionBrinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension; Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution; Subject's habitual PGA monotherapy
    PhasePhase 4
    Registry statusCompleted

  • Efficacy of Dorzolamide as an Adjuvant After Focal Photocoagulation in Clinically Significant Macular Edema

    NCT02227745 · start 2014-01

    Registered record
    Registry ID
    NCT02227745
    Conditions
    Diabetic Retinopathy; Diabetic Macular Edema
    Interventions
    Dorzolamide hydrochloride (2%); Placebo Sodium hyaluronate 4mg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2014-01
    Completion
    2015-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Retinopathy; Diabetic Macular Edema
    InterventionDorzolamide hydrochloride (2%); Placebo Sodium hyaluronate 4mg
    PhaseNot recorded
    Registry statusUnknown

  • Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

    NCT01284166 · start 2013-07

    Registered record
    Registry ID
    NCT01284166
    Conditions
    Glaucoma; Ocular Hypertension
    Interventions
    dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2013-07
    Completion
    2014-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Ocular Hypertension
    Interventiondorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution
    PhasePhase 3
    Registry statusWithdrawn

  • Clinical Evaluation of Patients With X-linked Retinoschisis

    NCT02331173 · start 2012-11

    Registered record
    Registry ID
    NCT02331173
    Conditions
    X-linked Retinoschisis; XLRS
    Interventions
    Dorzolamide 2% TID or brinzolamide 1% TID
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-11
    Completion
    2016-10
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionX-linked Retinoschisis; XLRS
    InterventionDorzolamide 2% TID or brinzolamide 1% TID
    PhaseNot recorded
    Registry statusCompleted

  • Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves

    NCT01535768 · start 2012-02

    Registered record
    Registry ID
    NCT01535768
    Conditions
    Glaucoma
    Interventions
    Aqueous Suppressant Eye Drops
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2012-02
    Completion
    2020-06
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionAqueous Suppressant Eye Drops
    PhasePhase 4
    Registry statusUnknown

  • Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Glaucoma

    NCT01471158 · start 2010-09

    Registered record
    Registry ID
    NCT01471158
    Conditions
    Glaucoma
    Interventions
    Brinzolamide/Timolol Maleate Fixed Combination (AZARGA); Dorzolamide/timolol Maleate Fixed Combination (COSOPT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-09
    Completion
    2011-05
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionBrinzolamide/Timolol Maleate Fixed Combination (AZARGA); Dorzolamide/timolol Maleate Fixed Combination (COSOPT)
    PhasePhase 4
    Registry statusCompleted

  • COSOPT-S® Treatment Versus Acetazolamide Before Trabeculectomy

    NCT01228149 · start 2010-08

    Registered record
    Registry ID
    NCT01228149
    Conditions
    Glaucoma
    Interventions
    Trabeculectomy with preoperative Diamox/DexaEDO treatment; Trabeculectomy with preoperative Cosopt S treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-08
    Completion
    2014-04
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionTrabeculectomy with preoperative Diamox/DexaEDO treatment; Trabeculectomy with preoperative Cosopt S treatment
    PhasePhase 4
    Registry statusCompleted

  • Trusopt and Cosopt; Ocular Perfusion Pressure and Blood Flow: New Long-term Prospective Data

    NCT01145898 · start 2010-06

    Registered record
    Registry ID
    NCT01145898
    Conditions
    Glaucoma
    Interventions
    (Cosopt®, prostaglandin)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-06
    Completion
    2012-10
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    Intervention(Cosopt®, prostaglandin)
    PhaseNot recorded
    Registry statusCompleted

  • Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy

    NCT01257698 · start 2010-02

    Registered record
    Registry ID
    NCT01257698
    Conditions
    Macular Hole; Retinal Detachment
    Interventions
    Dorzolamide 2%-timolol 0.5% topical eyedrops
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-02
    Completion
    2013-06
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMacular Hole; Retinal Detachment
    InterventionDorzolamide 2%-timolol 0.5% topical eyedrops
    PhaseNot applicable
    Registry statusCompleted

  • Equivalence Study of Dorzolamide 2% Eye Drops Solution

    NCT00878917 · start 2009-04

    Registered record
    Registry ID
    NCT00878917
    Conditions
    Open Angle Glaucoma; Ocular Hypertension
    Interventions
    Dorzolamide 2 % eye drops solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-04
    Completion
    2010-02
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen Angle Glaucoma; Ocular Hypertension
    InterventionDorzolamide 2 % eye drops solution
    PhasePhase 3
    Registry statusCompleted